Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Most castration-sensitive prostate cancers(CSPC)with metastases progress to castration-resistant prostate cancer(CRPC)within a few years. In recent years, upfront treatment with second-generation antiandrogens, novel hormonal agents (ARSIs)and taxanes, administered at the mCSPC stage, has been developed and the evidence of delaying the time to reach CRPC has been reported. However, once the disease progresses to CRPC, there are few treatment options and no effective treatment sequence has been established. Ra223 as radiotherapy for bone metastases in mCRPC treatment has shown prolonged survival benefits, similar to ARSI and taxane-based anticancer drugs, and is widely used in Japan. Recently, prostate-specific membrane antigen(PSMA)-lutetium therapy, in which PSMA is coupled to 177Lutetium and administered systemically, has been developed in Western countries for mCRPC expressing PSMA and is an effective RI therapy that reduces bone and visceral metastases. It is expected to be covered by health insurance in Japan in the near future and is expected to be a promising treatment for mCRPC.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparison of Cost-Effectiveness Between Digital Health Interventions and Pharmacotherapy for Depression: Systematic Review.
J Med Internet Res
September 2025
School of Pharmacy, Sungkyunkwan University, Gyeonggi-do, Republic of Korea.
Background: Owing to the unique characteristics of digital health interventions (DHIs), a tailored approach to economic evaluation is needed-one that is distinct from that used for pharmacotherapy. However, the absence of clear guidelines in this area is a substantial gap in the evaluation framework.
Objective: This study aims to systematically review and compare the economic evaluation literature on DHIs and pharmacotherapy for the treatment of depression.
Participants' Perspectives on the iCareBreast Mobile-Based Perioperative Care Program for Women Undergoing Breast Cancer Surgery: Qualitative Process Evaluation.
JMIR Hum Factors
September 2025
KK Women's and Children's Hospital, Singapore, Singapore.
Background: Breast cancer treatment, particularly during the perioperative period, is often accompanied by significant psychological distress, including anxiety and uncertainty. Mobile health (mHealth) interventions have emerged as promising tools to provide timely psychosocial support through convenient, flexible, and personalized platforms. While research has explored the use of mHealth in breast cancer prevention, care management, and survivorship, few studies have examined patients' experiences with mobile interventions during the perioperative phase of breast cancer treatment.
View Article and Find Full Text PDFPlasma glucose and HbA1c discrepancy may indicate hemoglobinopathy: a case series.
Curr Med Res Opin
September 2025
Department of Internal Medicine, Taksim Training and Research Hospital, Istanbul, Turkey.
Introduction: Diabetes Mellitus is a chronic disease characterised by elevated plasma glucose (PG) levels. HbA1c has been widely utilized for diabetes diagnosis. However, certain conditions restrict its use.
View Article and Find Full Text PDFTuning the Electrical Property and Electronic Band Structures of Organic Semiconductors via Surface Tension.
J Phys Chem Lett
September 2025
National Laboratory of Solid-State Microstructures, School of Electronic Science and Engineering, Collaborative Innovation Center of Advanced Microstructures, Nanjing University, Nanjing 210093, P. R. China.
Stress engineering is an effective way to tune the performance of semiconductors, which has been verified in the work of inorganic and organic single-crystal semiconductors. However, due to the limitations of the vapor-phase growth preparation conditions, the deposited polycrystalline organic semiconductors are more susceptible to residual stress. Therefore, it is of great research significance to develop a low-cost stress engineering applicable to vapor-deposited semiconductors.
View Article and Find Full Text PDFSystemic Delivery of an mRNA-Encoding, Tumor-Activated Interleukin-12 Lock to Eliminate Tumors and Avoid Immune-Related Adverse Events.
Nano Lett
September 2025
Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha 410082, China.
Interleukin-12 (IL-12) is a robust proinflammatory cytokine that activates immune cells, such as T cells and natural killer cells, to induce antitumor immunity. However, the clinical application of recombinant IL-12 has been limited by systemic immune-related adverse events (irAEs) and rapid degradation. To address these challenges, we employed mRNA technology to encode a tumor-activated IL-12 "lock" fusion protein that offers both therapeutic efficacy and systemic safety.
View Article and Find Full Text PDF